Lilly, Sepracor Pursue Non-Selective Antidepressants; (R)-Fluoxetine Dropped
Executive Summary
Lilly's termination of (R)-fluoxetine commits the company to developing non-selective agents to continue its presence in the antidepressant market.
You may also be interested in...
Sepracor Sales Force Expansion To 1,900 Planned For Up To 10 New Products
Sepracor plans to add more than 1,700 sales reps in the next three years to support upcoming product launches, President and COO William O'Shea announced during a Dec. 4 analyst conference.
Sepracor Sales Force Expansion To 1,900 Planned For Up To 10 New Products
Sepracor plans to add more than 1,700 sales reps in the next three years to support upcoming product launches, President and COO William O'Shea announced during a Dec. 4 analyst conference.
Barr, FDA In Discussions On Trigger For Generic Prozac Exclusivity
Barr's 180 days of Waxman/Hatch exclusivity for generic fluoxetine could depend on FDA's determination of whether a brand name company's pediatric exclusivity supercedes generic exclusivity, Barr told analysts during its quarterly conference call Oct. 24.